Abstract:Epacadostat (EPA), the most advanced inhibitor targeting the indoleamine 2,3-dioxygenase 1 (IDO1), is a critical endogenous metabolic immune regulator. In preclinical melanoma models [1], EPA potentiated the antitumor efficacy of immune checkpoint blockers (ICB) in comparison to ICB monotherapy. Phase I/II clinical trials proved the excellent safety and significant IDO1 targeting ability of EPA [2]. Much to the disappointment, combing EPA with Keytruda (anti-PD-1 inhibitor) exerted zero numerical progression-free survival benefit versus Keytruda alone in a subsequent Phase III randomized clinical study (NCT02752074) in unresectable or metastatic melanoma patients [3]. Despite many reasons were blamed for this blockbuster failure such as dosing regimen and experimental designs, the poor pharmacokinetics of EPA is neglected [1]. Piggybacked by our previous success using sphingomyelin (SM)-derived drug nanotherapeutic strategy [4], recently, we developed a SM-derived EPA nanovesicle. The SM-EPA conjugate was bridged by an oxime-ester bond that is highly responsive to hydrolase cleavage in tumors [5]. Following the spontaneous self-assembly into liposomal nanovesicle (Epacasome), EPA was securely packaged in the lipid bilayer. We showed that Epacasome strengthened IDO1 suppression by reducing the production of kynurenine, and promoted T cell proliferation in a co-culture setting. Also, it markedly increased the intracellular uptake via clathrin-mediated endocytosis with highly efficient drug release inside cancer cells. Systematic pharmacokinetic and biodistribution studies demonstrated that free EPA was eliminated from the blood rapidly with a T 1/2 = 0.15 h. However, Epacasome significantly extended the circulation T 1/2 to ~4.72 h, drastically increasing area under curve (AUC: 1196.55 vs 7.81 μg/ml*h), mean residence time (MRT, 6.82 vs 0.22 h), and dramatically decreased volume of distribution (1.1 vs 5.97 μg/(μg/ml)). The improved pharmacokinetics allowed Epacasome a higher chance for tumor uptake based on the enhanced permeability and retention effect, resulting in 46.3-fold more EPA delivery to tumors compared to free EPA. More strikingly, Epacasome deepened tumor penetration and distribution, which are vital for improved IDO1 inhibition in tumors. Epacasome was superior to free EPA in reducing the tumor growth and prolonging mouse survival. It also synergized with anti-PD-1 inhibitor to further fortify the IFN-γ and granzyme-B-mediated cytotoxic T lymphocytes (CTLs) immunity. Meanwhile, this combination regimen repolarized macrophage to inflammatory M1 phenotype, attenuated granulocyte myeloid-derived suppressor cells and the Foxp3 + Tregs, and enhanced CD80 + /CD86 + and CD103 + dendritic cells in B16-F10 melanoma model. These improved anti-melanoma efficacy and immune responses were found to be CD8 T cell dependent and attributed to the boosted IDO1 inhibition as reflected by the greatly increased tryptophan/kynurenine ratios in both plasma and tumor.

Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans

In Vitro Metabolism of E2, G2: Novel Bile Acid-Coupling Camptothecin Analogues, in Rat Liver Microsomes

Metabolism of ebracteolata compound B studied in vitro with human liver microsomes, HepG2 cells, and recombinant human enzymes.

Characterization of the Metabolism of Eupalinolide A and B by Carboxylesterase and Cytochrome P450 in Human Liver Microsomes

The metabolic fate of izencitinib, a gut-selective pan-JAK inhibitor, in humans. Identification of unusual fecal metabolites and implications for MIST evaluation

Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5

Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human

Comparison of the in vitro metabolism of psoralidin among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes.

The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite

Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the Immunoproteasome

Sphingomyelin-derived epacadostat nanovesicle enhances IDO1 inhibition for improved melanoma combination immunotherapy

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data

Pharmacokinetics (PK) of epacadostat in combination with sirolimus in advanced malignancy.

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

Design, Synthesis And Biological Evaluation Of Novel 1,2,5-Oxadiazol-3-Carboximidamide Derivatives As Indoleamine 2, 3-Dioxygenase 1 (Ido1) Inhibitors

Advanced piperazine-containing inhibitors target microbial β-glucuronidases linked to gut toxicity

Gut microbiota biotransformation of drug glucuronides leading to gastrointestinal toxicity: Therapeutic potential of bacterial β-glucuronidase inhibition in mycophenolate-induced enteropathy

Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid

Novel Interactions between Gut Microbiome and Host Drug-Processing Genes Modify the Hepatic Metabolism of the Environmental Chemicals Polybrominated Diphenyl Ethers